ReviewPulmonary therapy2022
Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation.
Review in Pulmonary therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Utilization and Outcomes of Septuagenarian Donation After Circulatory Death Donors.Transplantation direct · 2026Article
- Research advances in consistency and variability inJournal of thoracic disease · 2026Review
- Venous Thromboembolism in Brain-Dead Organ Donors: A Prospective Study of Prevalence, Management, and Impact on Organ Utilization and Recipient Outcomes.Clinical transplantation · 2026Observational
- A custom preservation solution extends the ex vivo availability of living heart valves for transplantation.JTCVS open · 2025Article
- Lung Ischemia-Reperfusion Injury in Lung Transplant Surgery: Where Do We Stand?Antioxidants (Basel, Switzerland) · 2025Review
- Article
- Donation-after-circulatory-death lungs narrow the survival gap between single- and bilateral-lung transplants: A propensity-matched analysis.JTCVS techniques · 2025Article
- Metabolite-enhanced normothermic machine perfusion improves kidney transplant viability.JCI insight · 2025Article
- Extended travel for donor organs: Is cold static storage still relevant.World journal of transplantation · 2025Article
- Nrf2/HO-1 Pathway Mediated Protective Effects of Hydrogen in a Model of Lung Transplantation Simulated by Rat Pulmonary Microvascular Endothelial Cells.Cell biochemistry and biophysics · 2025Article
- Outcomes of lung transplants utilizing donors from outside the continental United States.JHLT open · 2025Article
- Outcomes associated with remote, centralized ex vivo lung perfusion (rc-EVLP) for donor lungs in a real-world setting.JTCVS open · 2025Article
- Breathing New Life Into Donation After Circulatory Death (DCD) Lung Transplantation: The Role of Machine Perfusion.Cureus · 2025Review
- Challenges and opportunities in organ donation after circulatory death.Journal of internal medicine · 2025Review
- Computational physiological modeling for lung-specific ventilation and perfusion management inFrontiers in physiology · 2025Article
- Normothermic regional perfusion for donation after circulatory death in lung transplantation.Frontiers in cardiovascular medicine · 2025Review
- Pushing the Survival Bar Higher: Two Decades of Innovation in Lung Transplantation.Journal of clinical medicine · 2024Review
- Review
- A Cardioprotective perfusion protocol limits myocardial functional decline during ex situ heart perfusion.JHLT open · 2024Article
- Long-term outcomes of lung transplantation withFrontiers in transplantation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of waitlisted lung transplant candidates exceeds the availability of donor organs. Barriers to utilization of donor lungs include suboptimal lung allograft function, long ischemic times due to geographical distance between donor and recipient, and a wide array of other logistical and medical challenges. Ex vivo lung perfusion (EVLP) is a modality that allows donor lungs to be evaluated in a closed circuit outside of the body and extends lung donor assessment prior to final acceptance for transplantation. EVLP was first utilized successfully in 2001 in Lund, Sweden. Since its initial use, EVLP has facilitated hundreds of lung transplants that would not have otherwise happened. EVLP technology continues to evolve and improve, and currently there are multiple commercially available systems, and more under investigation worldwide. Although barriers to universal utilization of EVLP exist, the possibility for more widespread adaptation of this technology abounds. Not only does EVLP have diagnostic capabilities as an organ monitoring device but also the therapeutic potential to improve lung allograft quality when specific issues are encountered. Expanded treatment potential includes the use of immunomodulatory treatment to reduce primary graft dysfunction, as well as targeted antimicrobial therapy to treat infection. In this review, we will highlight the historical development, the current state of utilization/capability, and the future promise of this technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.